Photo of Morgan Schreurs

Morgan Schreurs

Morgan Schreurs represents and counsels clients in matters presenting significant legal, political, or reputational risk. She guides and supports clients pursuing public policy strategies, represents clients facing congressional investigations, and conducts workplace culture investigations and institutional culture assessments.

Prior to joining Covington, Morgan served as an Oversight & Investigations Law Clerk to the U.S. Senate Committee on Health, Education, Labor & Pensions (HELP) and provided Minnesota State government relations support to principal lobbyists for a food and consumer-products trade association and a health and disability non-profit organization. In Minnesota, Morgan was active in agriculture policy advocacy and education.

Morgan also supported federal, state, and local political candidates while working for a political non-profit organization in Minnesota and assisted with Advance on a 2016 presidential campaign.

As we reported in our prior client advisory on the wave of investigations to follow the pandemic, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act established three new bodies to conduct oversight and investigations on pandemic-related issues. Separately, House Speaker Nancy Pelosi announced a special committee to conduct additional pandemic-related oversight. In recent weeks,

On March 30, 2020, the inspectors general of several major agencies selected the Department of Defense Inspector General, Glenn Fine, to lead a newly created federal oversight entity that will investigate waste, fraud, and abuse in connection with the massive new coronavirus economic relief legislation. The inspectors general were exercising new authority contained in the

Although a final version of the Coronavirus Aid, Relief, and Economic Security (CARES) Act is not yet available, based on what we know so far, it appears that the legislation will include the provisions described below establishing oversight functions for the use of stimulus and bailout funds.  According to a number of sources, the bill

Consistent with popular predictions and our prior posts, Congress made drug pricing a key item on its investigative agenda in the first year of the 116th Congress.  Several factors contributed to the uptick in congressional drug pricing oversight activity, including the elevation of new Democratic chairs in the House with longstanding interests in drug